Kronos Bio, Inc.
NASDAQ:KRON
0.9 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Kronos Bio, Inc. |
Symbool | KRON |
Munteenheid | USD |
Prijs | 0.9 |
Beurswaarde | 54,265,140 |
Dividendpercentage | 0% |
52-weken bereik | 0.69 - 1.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Norbert W. Bischofberger Ph.D. |
Website | https://kronosbio.com |
An error occurred while fetching data.
Over Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)